^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    docetaxel

    i
    Other names: NSC628503, NSC-628503, RP56976, RP-56976, XPR6976, NSC 628503, RP 56976, XPR 6976, XRP-6976
    Company:
    Generic mfg.
    Drug class:
    Microtubule inhibitor
    Related drugs:
    2d
    A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) (clinicaltrials.gov)
    P1/2, N=360, Recruiting, Merck Sharp & Dohme LLC | Trial completion date: Feb 2030 --> Apr 2031 | Trial primary completion date: Feb 2030 --> Apr 2031
    Trial completion date • Trial primary completion date
    |
    docetaxel • Xtandi (enzalutamide) • abiraterone acetate • ifinatamab deruxtecan (DS-7300) • opevesostat (MK-5684)
    2d
    KLK2-PASenger: A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer (clinicaltrials.gov)
    P3, N=171, Recruiting, Janssen Research & Development, LLC | Not yet recruiting --> Recruiting
    Enrollment open
    |
    IL6 (Interleukin 6)
    |
    docetaxel • prednisone • pasritamig (JNJ-8343)
    2d
    A clinical study of V940 in people with non-small cell lung cancer (V940-013) (2025-520902-37-00)
    P1/2, N=15, Not yet recruiting, Merck Sharp & Dohme LLC
    New P1/2 trial
    |
    Keytruda (pembrolizumab) • carboplatin • docetaxel • albumin-bound paclitaxel • intismeran autogene (mRNA-4157)
    3d
    Comprehensive toxicity profile of the 4AC-4THP neoadjuvant regimen in HER2-positive breast cancer: a multicenter real-world study in Vietnam. (PubMed, Front Oncol)
    The 4AC-4THP regimen-comprising doxorubicin and cyclophosphamide followed by docetaxel, trastuzumab, and pertuzumab-has been widely adopted as neoadjuvant treatment for HER2-positive breast cancer. Subclinical cardiac dysfunction was common but mild and manageable. These findings provide further support for its use in neoadjuvant settings with appropriate monitoring strategies, especially in real-world clinical settings with variable access to monitoring resources.
    Clinical • Journal • Real-world evidence
    |
    HER-2 (Human epidermal growth factor receptor 2)
    |
    HER-2 positive
    |
    Herceptin (trastuzumab) • docetaxel • Perjeta (pertuzumab) • doxorubicin hydrochloride • cyclophosphamide
    3d
    AKT1 phosphorylates PRMT7 to promote GLUD1 methylation and gastric cancer progression. (PubMed, Cell Death Dis)
    In xenograft models, PRMT7 inhibitor SGC3027 combined with chemotherapeutic drugs docetaxel (DTX) synergistically suppresses tumor growth. Collectively, this study identifies the AKT1-PRMT7-GLUD1 axis as a key regulatory pathway in gastric cancer, and highlights its potential as a therapeutic target.
    Journal
    |
    AKT1 (V-akt murine thymoma viral oncogene homolog 1) • PRMT7 (Protein Arginine Methyltransferase 7)
    |
    docetaxel
    3d
    Study of DS-1062a Versus Docetaxel in Previously Treated Advanced or Metastatic Non-small Cell Lung Cancer With or Without Actionable Genomic Alterations (TROPION-LUNG01) (clinicaltrials.gov)
    P3, N=605, Active, not recruiting, Daiichi Sankyo | Trial completion date: Jan 2026 --> Feb 2027
    Trial completion date
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)
    |
    EGFR mutation • EGFR L858R • EGFR exon 19 deletion • MET exon 14 mutation
    |
    docetaxel • Datroway (datopotamab deruxtecan-dlnk)
    3d
    Immunohistochemical biomarkers to predict adjuvant chemotherapy response in patients with early breast cancer in the MATADOR trial (BOOG 2005-02). (PubMed, Breast)
    Patients with TN EZH2low tumours benefit more from ddAC, while EZH2high have a better outcome after TAC. High tubulin expression may predict docetaxel benefit if adjusted for sTILs. Further research with more patients is needed to find the best use of these biomarkers.
    Journal • IO biomarker
    |
    HER-2 (Human epidermal growth factor receptor 2) • BCL2 (B-cell CLL/lymphoma 2) • CCND1 (Cyclin D1) • ABCB1 (ATP Binding Cassette Subfamily B Member 1) • TUBB3 (Tubulin beta 3 class III) • GSTP1 (Glutathione S-transferase pi 1) • MAPT (Microtubule Associated Protein Tau)
    |
    HER-2 positive • HR positive • HER-2 negative • HR positive + HER-2 negative
    |
    docetaxel • doxorubicin hydrochloride • cyclophosphamide
    4d
    MEDINDUCTION: Durvalumab in Combination With Docetaxel, Cisplatin and 5-FU for Locally Advanced Head and Neck Squamous Cell Carcinoma (clinicaltrials.gov)
    P1, N=14, Terminated, Gustave Roussy, Cancer Campus, Grand Paris | N=36 --> 14 | Unknown status --> Terminated; Toxicities due to the treatment, stop of enrollment
    Enrollment change • Trial termination
    |
    cisplatin • Imfinzi (durvalumab) • docetaxel • 5-fluorouracil
    4d
    A Phase III Study Evaluating YL201 Versus ICC in 2L ESCC (clinicaltrials.gov)
    P3, N=440, Not yet recruiting, MediLink Therapeutics (Suzhou) Co., Ltd.
    New P3 trial
    |
    paclitaxel • docetaxel • irinotecan • YL201
    4d
    FASN: Fatty Acid Synthase Inhibition in Castration Refractory Prostate Cancer (clinicaltrials.gov)
    P2, N=50, Recruiting, Wake Forest University Health Sciences | Trial completion date: Apr 2030 --> Mar 2028
    Trial completion date
    |
    docetaxel • cabazitaxel • omeprazole
    7d
    TROPION-Lung17: Phase III Study of Datopotamab Deruxtecan Versus Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous NSCLC Without Actionable Genomic Alterations (clinicaltrials.gov)
    P3, N=400, Recruiting, AstraZeneca | N=103 --> 400
    Enrollment change • Trial initiation date
    |
    HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    KRAS G12C • MET exon 14 mutation • KRAS G12
    |
    docetaxel • Datroway (datopotamab deruxtecan-dlnk)